Mathematical models in oncology aid in the design of drugs and understanding of their mechanisms of action by simulation of drug bio-distribution, drug effects, and interaction between tumour and healthy cells. The traditional approach in pharmacometrics is to develop and validate ordinary differential equation models to quantify trends at the population level. In this approach, time-course of biological measurements is modelled continuously, assuming a homogenous population. Another approach, agent-based models focus on the behaviour and fate of biological entities at the individual level which subsequently could be summarized to reflect the population level. Heterogeneous cell populations and discrete events are simulated, and spatial dis...
The decreasing cost and increasing scope and power of emerging genomic technologies are reshaping th...
Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AM...
The decreasing cost and increasing scope and power of emerging genomic technologies are reshaping th...
Model-informed precision dosing (MIPD) is a quantitative dosing framework that combines prior knowle...
Glioblastoma Multiforme (GBM) is a highly heterogeneous, damaging and aggressive form of brain tumor...
To reduce late stage attrition during drug development, and improve the diagnosis of drug induced li...
New Zn(II) complexes (ZnII-VS, ZnII-LS, ZnII-SS, ZnII-CS and ZnII-MS) of the sulfonamide antibiotic ...
Funding: Marie Slodowska Curie Fellowship, (Behaviour-Connect) funded by the EU Horizon2020 program ...
Carbon nanomaterials possess unique chemical and functional properties allowing for their applicatio...
Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhi...
Carbon nanomaterials possess unique chemical and functional properties allowing for their applicatio...
From Wiley via Jisc Publications RouterHistory: received 2021-05-17, rev-recd 2021-09-16, accepted 2...
Adenine, thymine and uracil thio-derived acyclonucleosides were synthesized and characterized by UV-...
Adenine, thymine and uracil thio-derived acyclonucleosides were synthesized and characterized by UV-...
FKB327 was approved by the European Medicines Agency as a biosimilar to European-authorized adalimum...
The decreasing cost and increasing scope and power of emerging genomic technologies are reshaping th...
Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AM...
The decreasing cost and increasing scope and power of emerging genomic technologies are reshaping th...
Model-informed precision dosing (MIPD) is a quantitative dosing framework that combines prior knowle...
Glioblastoma Multiforme (GBM) is a highly heterogeneous, damaging and aggressive form of brain tumor...
To reduce late stage attrition during drug development, and improve the diagnosis of drug induced li...
New Zn(II) complexes (ZnII-VS, ZnII-LS, ZnII-SS, ZnII-CS and ZnII-MS) of the sulfonamide antibiotic ...
Funding: Marie Slodowska Curie Fellowship, (Behaviour-Connect) funded by the EU Horizon2020 program ...
Carbon nanomaterials possess unique chemical and functional properties allowing for their applicatio...
Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhi...
Carbon nanomaterials possess unique chemical and functional properties allowing for their applicatio...
From Wiley via Jisc Publications RouterHistory: received 2021-05-17, rev-recd 2021-09-16, accepted 2...
Adenine, thymine and uracil thio-derived acyclonucleosides were synthesized and characterized by UV-...
Adenine, thymine and uracil thio-derived acyclonucleosides were synthesized and characterized by UV-...
FKB327 was approved by the European Medicines Agency as a biosimilar to European-authorized adalimum...
The decreasing cost and increasing scope and power of emerging genomic technologies are reshaping th...
Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AM...
The decreasing cost and increasing scope and power of emerging genomic technologies are reshaping th...